RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 -- It is with deep sadness that Pappas Capital announces the passing of Dr. Ernest Mario, Senior Venture Partner and one of the founders...
Pappas Portfolio
4DMT is focused on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need.
x
Achillion is a pharmaceutical company developing treatments for patients with challenging infectious diseases – hepatitis C and resistant bacterial infections. It went public in 2006.
x
Aclara Biosciences went public in 2000, powered by innovative microfluidics technology that automated genetic sequencing and other laboratory functions.
x
Pappas Ventures co-founded Afferent in December 2009, after recognizing a novel mechanism with high potential in the treatment of chronic pain and other areas of substantial medical need.
x
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers.
x
Allievex is developing novel therapies for the treatment of rare pediatric neurodegenerative diseases.
x
Amplyx was founded on a mission to develop a new class of antifungal medicine that would overcome the severe limitations of today’s therapy options.
x
Anthera is developing and commercializing novel therapeutics to treat serious human illnesses associated with inflammation. It went public in 2010.
x
Arena made its debut as a public company in 2000, with a focus (then and now) on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs).
x
ArgoMed developed a proprietary, water-induced thermotherapy device and technique to address the non-surgical treatment of benign prostatic hyperplasia (BPH).
x
Athersys is a biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease areas based on a stem cell platform called MultiStem®.
x
Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions.
x
BaroSense is a medical device company developing minimally invasive devices for the treatment of obesity, the largest global chronic disease in adults.
x
The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance.
x
BioAtla® develops novel monoclonal antibody and cell based therapeutics using their proprietary platoforms.
x
BioSyntech focused on biotherapeutic thermogels for regenerative medicine.
x
BrainCells (BCI) is a neurogenesis-based drug discovery and development company targeting novel therapeutics for depression, mood disorders and other central nervous system diseases.
x
Calyx Therapeutics was acquired by Theracos in 2003.
x
CardioDx is a molecular diagnostics company commercializing tools to assist cardiologists in the diagnosis of cardiovascular disease.
x
CeNeRx focused on developing treatments for diseases of the central nervous system.
x
Cequent Pharmaceuticals was acquired by Marina Biotech in 2010.
x
Cerexa was acquired by Forest Laboratories in 2007.
x
Chimerix is developing a range of oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. It went public in April 2013.
x
Cognetix explored the use of snail toxins for the treatment of epilepsy, pain and anesthesia.
x
CoLucid is a clinical stage company developing therapeutics intended for migraine patients who don’t respond well, or at all, to triptan-based drugs.
x
CuraSen Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative diseases.
x
Curis was formed in 2000 from a merger of Pappas portfolio company Reprogenesis with Ontogeny and Creative BioMolecules.
x
Curzion Pharmaceuticals is a clinical-stage company, co-founded by Pappas Capital, focused on developing treatments for rare fibrotic diseases.
x
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.
x
Developed drugs for irritable bowel syndrome and other gastrointestinal disorders.
x
EBM Solutions was acquired by HealthGate Data Corp. in 2003.
x
Elitra’s assets were acquired by Merck in 2004.
x
Emerald is dedicated to the development of naturally occurring biochemicals for crop enhancement.
x
Enlaza is developing novel classes of protein therapeutics to deliver more efficacious and safer treatments for patients.
x
Envisia focuses on the development of novel ocular therapies.
x
FlowCardia was acquired by C. R. Bard in 2010.
x
Gentis develops novel, biomaterials-based products intended to treat spinal disc disease.
x
IlluminOss has developed a groundbreaking, minimally invasive orthopedic system for the stabilization and treatment of bone fractures.
x
Istari Oncology is a clinical-stage biotechnology company focused on developing innovative immuno-oncology platforms for the treatment of solid tumors, including glioblastoma and melanoma.
x
Kezar Life Sciences is a clinical stage company developing novel small molecule therapeutics to treat autoimmune disorders and malignant diseases.
x
LEAD was acquired by BioMarin Pharmaceutical in 2010.
x
LipoScience is building out personalized diagnostic tests for a range of metabolic and other diseases. The company went public in January 2013.
x
Liquidia Technologies uses novel nanoparticle technology platforms to develop innovative healthcare products.
x
Lumena, which was acquired by Shire plc in June 2014, is developing oral therapeutics for adults and children suffering from rare and debilitating liver diseases.
x
Marina is developing and commercializing therapeutic products for rare diseases based on RNA interference (RNAi).
x
Milestone Pharmaceuticals is a cardiovascular drug development company focused on the treatment of transient cardiovascular conditions such as supraventricular tachycardia.
x
Mirati is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer.
x
Mirum is developing a novel approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions.
x
Nereus utilized specialized research out of the Scripps Institution of Oceanography.
x
NuVasive’s broad suite of minimally invasive products covers the breadth of the spine market. NuVasive went public in 2004.
x
In 2010 Optherion entered into a diagnostic alliance with Sequenom and licensed its technology for therapeutic applications to Baxter.
x
Orphomed is a clinical stage biotechnology company focused on the development of best-in-class therapies for the treatment of inadequately-controlled gastrointestinal disorders.
x
Panacos went public via a reverse merger with V.I. Technologies in 2005.
x
Peninsula Pharmaceuticals was acquired by Johnson & Johnson in 2005.
x
Plexigen focused on instrumentation and service for genetic and proteomic testing.
x
Daiichi Sankyo acquired Plexxikon in 2011 for $935 million.
x
Reneo Pharmaceuticals is a clinical-stage start-up company focused on developing treatments for rare metabolic disorders
x
Ribometrix is a biotechnology company developing small molecule therapeutics that target RNA to treat human diseases.
x
Rotation Medical has developed a proprietary, minimally invasive rotator cuff implant system for the treatment of rotator cuff disease.
x
Selventa is delivering personalized medicine through computational systems biology for drug discovery and development.
x
Sensys focused on advancing technology for non-invasive blood glucose monitoring.
x
Signase assets were acquired by Systems Medicine Inc. in 2005.
x
Sorriso is advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases.
x
Spherics developed an oral delivery technology platform.
x
Syndax is a late stage oncology company using epigenetics, a novel way to control gene regulation, to overcome the problem of resistance seen with oncology treatments.
x
Syntonix was acquired by Biogen Idec in 2007.
x
TargeGen was acquired by Sanofi-Aventis in 2010.
x
TESARO is an oncology-focused biopharmaceutical company developing and providing safer and more effective therapeutics and supportive care products. It went public in 2012.
x
Thrasos is a clinical stage therapeutics company discovering and developing targeted therapies for the prevention and treatment of kidney disease.
x
Tune Therapeutics s developing an in vitro epigenetic editing platform for activating and repressing different genes across a wide number of indications.
x
TYRX, which was acquired by Medtronic, Inc. in early 2014, develops and sells implantable, combination drug and device products using novel biomaterials with a wide variety of clinical applications.
x
Ultragenyx is dedicated to life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases. It went public in January 2014.
x
Variagenics went public in 2000 (Nasdaq) and merged into Hyseq in 2002.
x
VelosBio Inc. is a near-term clinical-stage biopharmaceutical company focused on novel cancer targets.
x
Based on an understanding of the 12-LOX pathway and molecular mechanisms of immuno-inflammatory diseases, Veralox's efforts are leading to novel treatment paradigms and better outcomes for patients.
x
Exelixis acquired X-Ceptor in 2004.
x
